AbbVie ' s Two-Decade Humira Monopoly Ends With Amgen ' s 55% Discounted Knockoff

AbbVie's (ABBV) two-decade Humira monopoly came to an end Tuesday after Amgen (AMGN) launched its biosimilar knockoff at a 55% discount to the original. But AbbVie stock was mostly unmoved. The biosimilar called Amjevita is the first to hit the U.S. market. But through deals with AbbVie, a handful…#abbvie #humira #amgen #amgn #amjevita #murdogordon #abbviestock #richardgonzalez #organon #ogn

Source: Reuters: Health - January 31, 2023 Category: Consumer Health News Source Type: news